Drugs / V4020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07088822 | Aug 2025 → Feb 2026 overdue | Venezuelan equine encephalitis | Medigen, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V4020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07088822 ↗ |
| Modality | Vaccine | “novel Venezuelan Equine Encephalitis virus (VEEV) vaccine (V4020)” NCT07088822 ↗ |
| Route | Intramuscular | “administered by subcutaneous or intramuscular injection” NCT07088822 ↗ |
| Route | Subcutaneous | “administered by subcutaneous or intramuscular injection” NCT07088822 ↗ |